×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
SAVA – cassava sciences, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
SAVA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/27
07:11 am
sava
IGC Pharma posts promising interim data for Alzheimer's therapy [Yahoo! Finance]
Low
Report
IGC Pharma posts promising interim data for Alzheimer's therapy [Yahoo! Finance]
3/26
08:13 pm
sava
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study [Yahoo! Finance]
Low
Report
SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study [Yahoo! Finance]
3/26
04:17 pm
sava
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug [Yahoo! Finance]
Low
Report
Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug [Yahoo! Finance]
3/25
11:58 am
sava
Cassava Sciences, Inc. (NASDAQ: SAVA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
Medium
Report
Cassava Sciences, Inc. (NASDAQ: SAVA) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.
3/25
09:07 am
sava
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data [Yahoo! Finance]
High
Report
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data [Yahoo! Finance]
3/25
08:05 am
sava
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
High
Report
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
3/4
12:27 pm
sava
Cassava Sciences, Inc. (NASDAQ: SAVA) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Medium
Report
Cassava Sciences, Inc. (NASDAQ: SAVA) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
3/3
07:37 am
sava
Cassava Sciences Reports 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Cassava Sciences Reports 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Symbol
Headline
Impact
4/3
04:01 pm
sava
Form PRE 14A CASSAVA SCIENCES INC For: May 23
Low
Report
Form PRE 14A CASSAVA SCIENCES INC For: May 23
3/25
08:15 am
sava
Form 8-K CASSAVA SCIENCES INC For: Mar 25
High
Report
Form 8-K CASSAVA SCIENCES INC For: Mar 25
3/11
04:00 pm
sava
Form 8-K CASSAVA SCIENCES INC For: Mar 06
Medium
Report
Form 8-K CASSAVA SCIENCES INC For: Mar 06
3/3
04:20 pm
sava
Form 10-K CASSAVA SCIENCES INC For: Dec 31
Medium
Report
Form 10-K CASSAVA SCIENCES INC For: Dec 31
3/3
07:40 am
sava
Form 8-K CASSAVA SCIENCES INC For: Mar 03
Low
Report
Form 8-K CASSAVA SCIENCES INC For: Mar 03
2/27
07:32 am
sava
Form 8-K CASSAVA SCIENCES INC For: Feb 27
Medium
Report
Form 8-K CASSAVA SCIENCES INC For: Feb 27
1/7
04:40 pm
sava
Form 8-K CASSAVA SCIENCES INC For: Jan 07
Medium
Report
Form 8-K CASSAVA SCIENCES INC For: Jan 07
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/20
Form 4 CASSAVA SCIENCES INC For: Dec 20 Filed by: ROBERTSON SANFORD
60.3%
12/31 Form 4 CASSAVA SCIENCES INC For: Dec 31 Filed by: BARBIER REMI 37.1%
4/23 Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of Health 32.9%
12/26 Form 4/A CASSAVA SCIENCES INC For: Dec 18 Filed by: BARBIER REMI 29.3%
1/28 Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease 20.8%
9/3 Cassava Sciences to Present at H.C. Wainwright’s 21st Annual Global Investment Conference 17.9%
12/19 Form 4 CASSAVA SCIENCES INC For: Dec 19 Filed by: ROBERTSON SANFORD 17.5%
3/19 Cassava Sciences Announces Clinical Update and Business Progress Across Neuroscience Pipeline 17.2%
4/9 Form S-3/A CASSAVA SCIENCES INC 16.5%
1/15 Cassava Sciences Inc (NASDAQ: SAVA) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 14.5%
12/31 Form 4 CASSAVA SCIENCES INC For: Dec 31 Filed by: BARBIER REMI 37.1%
4/23 Cassava Sciences Announces New $2.5 Million Research Grant Award from National Institutes of Health 32.9%
12/26 Form 4/A CASSAVA SCIENCES INC For: Dec 18 Filed by: BARBIER REMI 29.3%
1/28 Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease 20.8%
9/3 Cassava Sciences to Present at H.C. Wainwright’s 21st Annual Global Investment Conference 17.9%
12/19 Form 4 CASSAVA SCIENCES INC For: Dec 19 Filed by: ROBERTSON SANFORD 17.5%
3/19 Cassava Sciences Announces Clinical Update and Business Progress Across Neuroscience Pipeline 17.2%
4/9 Form S-3/A CASSAVA SCIENCES INC 16.5%
1/15 Cassava Sciences Inc (NASDAQ: SAVA) was downgraded by analysts at Zacks Investment Research from a "strong-buy" rating to a "hold" rating. 14.5%
TOP News Decliners
12/6
Cassava Sciences Inc (NASDAQ: SAVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock, up previously from $3.00.
-21.8%
9/9 Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer’s Patients -15.9%
1/6 Are Insiders Buying Cassava Sciences, Inc. (NASDAQ:SAVA) Stock? [Yahoo! Finance News] -9.6%
1/7 Form SC 13G/A CASSAVA SCIENCES INC Filed by: HIRSCHMAN ORIN -9.4%
6/25 Cassava Sciences Inc (NASDAQ: SAVA) is now covered by analysts at Maxim Group. They set a "buy" rating on the stock. -8.5%
1/24 Cassava Sciences Inc (NASDAQ: SAVA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock. -8.0%
8/1 Cassava Sciences Inc (NASDAQ: SAVA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock. -7.6%
8/12 Q2/2019 6/30/2019 EPS -0.060 ZacksConsensus -0.120 ActVsEst 0.060 - Beat -6.8%
3/27 Form S-3 CASSAVA SCIENCES INC -5.2%
10/19 Cassava Sciences Inc (NASDAQ: SAVA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -4.8%
9/9 Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer’s Patients -15.9%
1/6 Are Insiders Buying Cassava Sciences, Inc. (NASDAQ:SAVA) Stock? [Yahoo! Finance News] -9.6%
1/7 Form SC 13G/A CASSAVA SCIENCES INC Filed by: HIRSCHMAN ORIN -9.4%
6/25 Cassava Sciences Inc (NASDAQ: SAVA) is now covered by analysts at Maxim Group. They set a "buy" rating on the stock. -8.5%
1/24 Cassava Sciences Inc (NASDAQ: SAVA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock. -8.0%
8/1 Cassava Sciences Inc (NASDAQ: SAVA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $3.00 price target on the stock. -7.6%
8/12 Q2/2019 6/30/2019 EPS -0.060 ZacksConsensus -0.120 ActVsEst 0.060 - Beat -6.8%
3/27 Form S-3 CASSAVA SCIENCES INC -5.2%
10/19 Cassava Sciences Inc (NASDAQ: SAVA) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: